Business Wire

Forescout Addresses Modern SecOps Challenges with Launch of Forescout XDR

1.3.2023 18:00:00 EET | Business Wire | Press release

Share

Forescout Technologies Inc., the global leader in automated cybersecurity, today unveiled Forescout XDR, to help enterprises better detect, investigate, and respond to the broadest range of advanced threats, across the extended enterprise.

A typical SOC is flooded with 450 alerts per hour1, and analysts waste precious time trying to correlate low fidelity alerts and chasing false positives, often at the expense of focusing on legitimate attacks. Until now, a security operations center’s (SOC) field of view for threat detection and response has excluded critical devices that are increasingly common points of attack, including operational technology (OT), industrial control systems (ICS), building management systems (BMS), and medical and IoT devices. In addition, the technology stack that SecOps teams have had to rely on has made it difficult to respond to these threats in a rapid and comprehensive manner.

“The true value of an XDR solution lies in its ability to ingest telemetry and data from across the entire enterprise: cloud, campus, remote and datacenter environments, and every managed and unmanaged connected device. This is what the X in XDR is all about, after all,” said Justin Foster, CTO, Forescout. “Traditional XDR products lack this capability, or they only leverage data from the vendor’s own EDR or a few other security tools. This significantly limits the flexibility, scalability and effectiveness that an XDR solution must provide.”

Through the advanced application of data science and automation, Forescout XDR generates one high-fidelity alert that truly warrants analyst investigation, from every 50 million logs ingested, per hour2. Because Forescout XDR is vendor- and EDR-agnostic, this ingestion includes data from over 170 security, infrastructure, application, cloud/SaaS and enrichment sources, and dozens of leading vendors. And with over 70 sources of threat intelligence and 1500 verified detection rules and models, and data onboarding included, Forescout XDR customers can be operational within hours, actively detecting, investigating, and responding to threats.

“Forescout XDR, with the breadth and richness of its capabilities, particularly its dashboards and reporting, provides an out-of-the-box solution to SOC challenges that we spent 18-24 months trying to address,” said Samer Mansour, CISO, Panasonic Corporation of North America. “It was easy to deploy, and fully operational in a matter of weeks. And with its tight integration to Forescout’s network security and visibility solutions, and our broader security tech stack, it gives us the ability to exert a lot more control across our IT and OT environments, and further elevate our overall security.”

Seamless integration with Forescout’s industry-leading network access control solution helps ensure that customers can:

  1. Reduce the attack surface, and the risk of an attack in the first place, by preventing compromised or non-compliant devices from connecting to their networks. This proactive approach to XDR further elevates the effectiveness and performance of a modern SOC.
  2. Automate response workflows that can immediately touch every managed and unmanaged connected device, across the enterprise. This reduces an attack's blast radius in real-time, allowing proper mitigation or remediation measures to be completed.

Because Forescout XDR has a multi-tenant architecture and supports local data storage while also being able to provide an aggregated global view of threats and SOC performance, it is ideally suited to large enterprises, multi-nationals, organizations with regional SOCs and managed security service providers (MSSPs).

Pricing
SaaS licensing is based on the total number of endpoints in the enterprise. As such, customers have the flexibility to leverage the data sources needed to fully support the use cases important to them, and help ensure better detection, without concern for escalating or fluctuating costs associated with cloud log storage.

About Forescout
Forescout Technologies, Inc. delivers automated cybersecurity across the digital terrain, maintaining continuous alignment of customers’ security frameworks with their digital realities, including all asset types- IT, IoT, OT, IoMT, and cloud environments. The Forescout Platform provides complete asset visibility, continuous compliance, network segmentation and a strong foundation for Zero Trust. For more than 20 years, Fortune 100 organizations and government agencies have trusted Forescout to provide automated cybersecurity at scale. Forescout arms customers with data-powered intelligence to accurately detect risks and quickly remediate cyberthreats without disruption of critical business assets. www.forescout.com

Managing cyber risk, together.

1

“The 2020 State of Security Operations,” Forrester Consulting

2

Based on aggregate Forescout data from a 1-year period (Dec 2021-2022), across 30 enterprise customers, representing a range of company sizes and industries.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact:
Emily Alfano
Manager of PR
Emily.alfano@forescout.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release

Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release

Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development

Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye